@article {Shewcraft2022.09.02.22279503, author = {Ryan A. Shewcraft and Mitchell K. Higashi and Yeting Zhang and Jonathan Tyler and Lisa Y. Lau and Bryn D. Webb and Seungwoo Lee and Rajasekar Ramasamudram-Chakravarthi and Teresa A. Cacchione and Alan B. Copperman and Ashley Birch and Marra Francis and Lisong Shi and Lisa Edelmann and Rong Chen and Li Li and Eric Schadt}, title = {Real-world genetic screening with molecular ancestry supports comprehensive pan-ethnic carrier screening}, elocation-id = {2022.09.02.22279503}, year = {2022}, doi = {10.1101/2022.09.02.22279503}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We characterize the clinical utility and economic benefits of a comprehensive pan-ethnic carrier screening panel that spans 282 monogenic disease conditions in a large, diverse population of 397,540 reproductive health patients. For 142,049 of these patients, we were able to accurately estimate genetic ancestries across 7 major population groups. We examined individual carrier and at-risk carrier couple (ARCC) rates with respect to self-reported and genetic ancestries across ancestry-specific and pan-ethnic panels. Our results show that this comprehensive panel identified \>10-times the ARCCs compared with a two-gene pan-ethnic panel and provided a substantial benefit over ancestry-specific screening panels across the major population groups. Finally, we generated a universal cost-of-care model across the monogenic disease conditions represented on the comprehensive pan-ethnic carrier screening panel to demonstrate potential healthcare savings in addition to the demonstrated clinical benefits that could be realized adopting this type of panel as standard of care for all.Competing Interest StatementL.L., R.C., E.S., R.S., M.K.H., Y.Z., J.T., L.Y.L, S.L., B.W., A.B.C., R.C., M.F., L.S., L.E. are formerly or currently employed by Sema4. T.A.C. and A.B.C. are employed by Reproductive Medicine Associates of New York.Funding StatementNo funding is supported for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Western Institutional Review Board and Ethics committee of Mount Sinai School of Medicine in accordance with Mount Sinai Federal Wide Assurances gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original carrier screening results data are from Sema4 genetic counselor reports. Carrier rate and ARCC rate summary statistics are available in Supplementary Table 5 and Supplementary Table 7.}, URL = {https://www.medrxiv.org/content/early/2022/09/04/2022.09.02.22279503}, eprint = {https://www.medrxiv.org/content/early/2022/09/04/2022.09.02.22279503.full.pdf}, journal = {medRxiv} }